News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Exelixis, Inc. (EXEL) Announces Data Presentations at ESMO 2012 Congress


9/17/2012 9:30:09 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that its lead compound, cabozantinib, will be the subject of three clinical data presentations at the European Society for Medical Oncology (ESMO) 2012 Congress. During the meeting, which will be held from September 28 to October 2, 2012, in Vienna, Austria, investigators will present data from ongoing trials of cabozantinib in medullary thyroid cancer, castration-resistant prostate cancer, and non-small cell lung cancer.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES